Antibody-conjugated nanoparticles for target-specific drug delivery of chemotherapeutics

Scholarly Works

• Feizy, M.; Nehal, N.; Haider, F.; Khan, M.; Khan, S.; Parveen, R.; Amin, S.; Ali, J. Advanced nanomedicine-based strategies for glioblastoma management: Targeted delivery, photodynamic therapy, and theranostic integration. Journal of Drug Delivery Science and Technology 2026, 124, 108652. doi:10.1016/j.jddst.2026.108652
• Pourmasoumi, P.; Zamani, F.; Bayat, M.; Amini, A. Bevacizumab-Functionalized Exosome-Associated Chitosan Nanocomposite for Temozolomide Delivery and Apoptosis-Related Transcriptional Modulation in Experimental Glioma. International journal of nanomedicine 2026, 21, 643605–26. doi:10.2147/ijn.s643605
• Busato, D.; Argenziano, M.; Polano, M.; Capolla, S.; Mossenta, M.; Tangredi, C.; Riccardi, F.; Mangogna, A.; Durigutto, P.; Fontana, G.; De Leo, L.; Sblattero, D.; Macor, P.; Toffoli, G.; Cavalli, R.; Bo, M. D. The anti-GPC1 antibody AT101 as effective targeting agent for chemotherapeutic-loaded chitosan nanobubbles in the treatment of pancreatic adenocarcinoma. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 2026, 204, 119956. doi:10.1016/j.biopha.2026.119956
• Visan, A. I.; Anghel, S.; Negut, I.; Hapenciuc, C. Bioinspired and biomimetic nanomaterials for advancing nanomedicine. Precision Nanomedicine; Elsevier, 2026; pp 137–166. doi:10.1016/b978-0-443-45321-2.00005-9
• Zhang, B.; Zhao, Y.; Liu, X.; Huang, R.; Zhou, Y.; Ye, J.; Li, J.; Xu, Z.; Cui, W.; Yu, J.; Wang, Y.; Liu, H. Self-assembled nanocomplexes of polyphenol-modified prodrugs and transferrin enable cascade-targeted and redox-activated chemotherapy. Materials horizons 2026, 13, 9230–9246. doi:10.1039/d6mh00886k
• Singaravelu, S.; Balu, R.; Senthilkumar, C.; Jayaprakash, J. Smart biomaterials for precision drug delivery: emerging strategies for site-specific targeting and controlled therapeutic release. Frontiers in Biomaterials Science 2026, 5. doi:10.3389/fbiom.2026.1912922
• Rajapaksha, W.; Eldi, P.; Gillam, T. A.; Blencowe, A.; Garg, S.; Albrecht, H.; Khetan, R. Receptor Co‑targeting Strategies for Personalized Ovarian Cancer Therapy. International journal of nanomedicine 2026, 21, 633450–16. doi:10.2147/ijn.s633450
• Knani, I.; Habib, Y.; Kaneti, G.; Shayderman, O.; Alyan, M.; Abu-Raiya, T.; Shklover, J.; Schroeder, A. Rapid Fc-mediated surface modification of liposomes with antibodies for selective targeting of pancreatic tumors. Journal of controlled release : official journal of the Controlled Release Society 2026, 399, 115319. doi:10.1016/j.jconrel.2026.115319
• Feng, H.; Liu, B. Ultrahigh-DAR antibody-drug conjugates: advancing the next generation of targeted therapy. Antibody therapeutics 2026, 9, 566–575. doi:10.1093/abt/tbag042
• Jung, D. H.; Jeong, S. Y.; Cho, Y.; Lee, C. Y.; Cho, H. H.; Liu, J.; Heo, J. H.; Lee, J. H. Gold nanoparticle-based colorimetric sensors for virus detection: Design principles, recent advances, and perspectives. Materials Today Nano 2026, 35, 100900. doi:10.1016/j.mtnano.2026.100900
• Joo, K. S.; Kwon, I. A.; Park, J.-Y.; Khang, D. Nanodrug-mediated strategies for targeting the undruggable: Comparative perspectives on targeted protein degradation and stabilization. Materials Today Nano 2026, 35, 100941. doi:10.1016/j.mtnano.2026.100941
• Prachyathipsakul, T.; Gupta, P.; Thayumanavan, S. K.; Vijay, S.; Kannan, K.; Thayumanavan, S. Linker Chemistry in Antibody-Drug Conjugates: Current Strategies, Clinical Pharmacokinetic Analyses, and Linker-Free Outlooks. Bioconjugate chemistry 2026, 37, 1507–1515. doi:10.1021/acs.bioconjchem.6c00299
• Damough, S.; Damough, S.; Mafakher, L.; Heshmati, M.; Adeli, A.; Talebkhan, Y. Current Applications of Staphylococcal Protein A in Biotechnology and Biomedicine: A Comprehensive Review. Biotechnology and bioengineering 2026, 123, 2884. doi:10.1002/bit.70307
• Pang, N. Y.-L.; Pang, A. S.-R.; Pang, K. Y.-L.; Dinesh, T.; Wang, D.-Y.; Srinivasan, D. K. Advancing Otology through Nanoparticle-Based Interventions for Inner Ear Treatment. ACS Applied Nano Materials 2026, 9, 13649–13666. doi:10.1021/acsanm.6c01453
• Asad Pour, O.; Opazo, F.; Rostamzadeh, J.; Ghanam, J.; Chetty, V. K.; Hila, A.; Neumann, U.; Hetze, S.; Barthel, L.; Best, J.; Schmidt, H. H.; Thakur, B. K. Combinational CSF1R/PD-L1 targeting by BM-MSC-derived exosome–liposome hybrid orchestrates tumor-associated macrophage phagocytosis in an in vitro tumor-microenvironment-dependent manner. Cancer Nanotechnology 2026, 17. doi:10.1186/s12645-026-00402-0
• Shadab, A.; Haider, M. F.; Abohassan, M. Lipid Nanoparticles Based Drug Delivery Systems: Design Innovations, Therapeutic Applications, and Translational Progress. Journal of Pharmaceutical Innovation 2026, 22. doi:10.1007/s12247-026-10876-5
• Rocchi, A.; Marchetti, L.; Decuzzi, P.; Teesalu, T.; Celia, C. Controlling nanoparticle targeting: from physicochemical design to molecular recognition. Nanomedicine (London, England) 2026, 21, 1989–2005. doi:10.1080/17435889.2026.2688999
• Nayak, P.; Swain, S. K.; Jogamaya Das, I.; Samal, H. B. Next-generation antibody-drug conjugated nanoparticles in metastatic breast cancer: Mechanism, clinical advances, and translational opportunities. Next Nanotechnology 2026, 10, 100558. doi:10.1016/j.nxnano.2026.100558
• Cui, S.; Ye, Z.; Arral, M. L.; Liu, L.; Weng, B.; Zhang, X.; Nair, R.; Zhao, Y.; Sahoo, J. K.; Gao, S.; Wang, Y.; Qu, Z.; Shi, Z.; Xu, Q.; Kaplan, D. L. Silk-Based Protein Corona Enhances mRNA-LNP Vaccine Efficacy and Prevents Tumor Relapse. Advanced materials (Deerfield Beach, Fla.) 2026, 38, e21487. doi:10.1002/adma.202521487
• Nikhar, S.; Jahan, A.; Mahato, T.; Giri, A. S. Peptide and Antibody Functionalized Nanoparticles: Active Targeting Strategies for Next-Generation Contrast Agents and Drug Delivery Systems. ACS Applied Nano Materials 2026, 9, 10448–10477. doi:10.1021/acsanm.5c05449

Explore citations to this article at